Members of the ACCC IO Institute Executive Committee discuss the importance of standardizing education for Immunotherapy patients and how designating a champion within your practice can play a critical role in the success of irAE identification and management.(features Sanjiv Agarwala, MD; and Niesha Griffith, MS, RPH, FASHP)
Many organizations have published formal recommendations, or workup guidelines, for managing irAEs, including ASCO, ESMO, NCCN, and SITC.The following can be used as a directory for the current irAE workup guidelines.
Our busy community practice first began treating patients with immunotherapy through participating in the original ipilimumab clinical trials. We quickly realized that this new treatment paradigm would require us to create and implement an effective screening and management tool for our immunooncology (IO) patient population.
Immune-related adverse events (irAEs) are extremely common in patients being treated with checkpoint inhibitors for advanced melanoma. The type, quality, and severity of these adverse events, however, varies by treatment regimen and by patient.
Download Article & Companion Guide